CJC-1295 / Ipamorelin

CJC-1295 and ipamorelin are two distinct peptides that target different steps of the growth hormone (GH) release cascade and are commonly stacked together in compounded formulations. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds GHRH receptors in the pituitary; the version with a Drug Affinity Complex (DAC) linker extends its half-life to approximately six to eight days by binding reversibly to albumin, allowing sustained GH and IGF-1 elevation [1]. The version without DAC (sometimes called "Mod GRF 1-29") has a shorter half-life of roughly 30 minutes and is dosed to coincide with meals or exercise.

Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor (GHSR-1a) agonist. Unlike older GH-releasing peptides, ipamorelin displays a high degree of selectivity for GH release with minimal stimulation of cortisol, prolactin, or ACTH in preclinical and early clinical data [5]. Combining a GHRH analog with a GHSR agonist is thought to amplify GH pulses synergistically, because the two pathways converge on the somatotroph cell through different receptor mechanisms.

The CJC-1295/ipamorelin combination is not FDA-approved. Both peptides are compounded and used off-label — primarily marketed for body composition, recovery, and anti-aging purposes. Published human clinical trial data on the combination itself are absent; available evidence consists of one small human study of CJC-1295 alone, limited human tolerability data for ipamorelin from a GI-motility trial, and broader review literature on GH-axis peptides. Claims about fat loss or muscle gain in healthy adults rest largely on extrapolation from physiology rather than direct human RCTs of the stack.

CJC-1295 binds GHRH receptors on anterior pituitary somatotrophs, triggering cAMP-mediated GH gene transcription and pulsatile GH secretion. The DAC modification couples the peptide covalently to circulating albumin via a reactive ester group, dramatically extending residence time and producing a sustained "tonic" rise in GH and IGF-1 rather than a physiological pulsatile pattern [1]. IGF-1 elevation is the proposed downstream mediator for protein synthesis, lipolysis, and tissue repair.

Ipamorelin mimics acylated ghrelin at GHSR-1a on both the pituitary and hypothalamus, amplifying GH release without substantially activating the HPA axis (cortisol) or lactotroph (prolactin) pathways [[cite:5],[cite:6]]. When co-administered with a GHRH analog, GHRH and ipamorelin act on separate but complementary receptor systems: GHRH increases somatotroph responsiveness while ghrelin-mimetics suppress the inhibitory tone of somatostatin, producing supra-additive GH pulses. This synergy is well-described mechanistically in preclinical models; human dose-response data for the combined stack are not yet published.

The most important human study of CJC-1295 is a 2006 phase 2 trial by Teichman et al. in 65 healthy adults (ages 21-61). Multiple subcutaneous doses of CJC-1295 (with DAC; 30-120 mcg/kg) produced dose-dependent, sustained increases in mean GH levels (2- to 10-fold above baseline) and IGF-1 (55-70% increases at higher doses). GH and IGF-1 elevations were maintained for six to seven days after a single injection, which the authors attributed to the albumin-binding half-life extension [1]. No comparison arm with ipamorelin was tested, and the study was not designed to measure body composition endpoints.

Ipamorelin\'s human tolerability profile comes partly from a 2014 proof-of-concept RCT (Beck et al.) in surgical patients, where ipamorelin was administered to accelerate return of GI function after bowel resection. Ipamorelin was well tolerated with no serious adverse events attributed to the drug, providing some reassurance about safety in a controlled clinical setting [4]. This study was not designed to assess body composition or GH-axis outcomes in healthy adults.

Recent narrative and systematic reviews of GH-axis peptides used in sports and aesthetic medicine acknowledge both CJC-1295 and ipamorelin as among the most widely self-administered compounds in this class, while noting that controlled human efficacy data for fat loss, muscle hypertrophy, or recovery in healthy subjects are lacking [[cite:2],[cite:3]]. One 2026 review covering over 20 GH-secretagogues concluded that patient self-administration has substantially outpaced the clinical trial evidence base, and that health claims circulating online are largely extrapolated from GH physiology rather than from human endpoints [2]. Evidence grade for this combination: **C** (plausible mechanism; one small human CJC-1295 pharmacokinetic study; no human RCT of the stack).

In preclinical models, ipamorelin robustly stimulates GH without activating the stress axis. A 2024 ferret study showed that ipamorelin and the related GHS anamorelin attenuated cisplatin-induced weight loss, consistent with the expected anabolic GH/IGF-1 response [5]. Preclinical findings support mechanistic plausibility but cannot be directly extrapolated to efficacy in healthy humans.

Providers who offer compounded CJC-1295/ipamorelin typically prescribe the combination in a single vial for subcutaneous injection. Common protocols use CJC-1295 (without DAC / Mod GRF 1-29) at 100 mcg combined with ipamorelin at 100-200 mcg, injected once daily — often at bedtime to align with the physiological overnight GH surge. When the DAC version is used, dosing frequency drops to once or twice per week given the extended half-life. Treatment cycles of 3-6 months followed by a rest period are often described, though these protocols are not derived from controlled trials.

Refrigeration is required for reconstituted peptide vials. Bacteriostatic water is the standard diluent. Injection sites (abdomen, thigh) should be rotated. Dosing should only occur under the supervision of a licensed prescriber who monitors IGF-1 levels to avoid excessive GH/IGF-1 exposure. There is no consensus, FDA-approved dosing protocol for healthy adults; all use is off-label and compounded formulations lack the standardization of FDA-approved drugs.

The most commonly reported adverse effects with CJC-1295 in the Teichman 2006 trial were injection-site reactions (pain, redness, swelling) in roughly one-third of subjects, along with transient facial flushing [1]. Ipamorelin was generally well tolerated in the Beck 2014 RCT [4]. Broader safety concerns with GH-axis peptide use include: elevated blood glucose (GH is counter-regulatory to insulin), fluid retention, carpal tunnel symptoms, and the theoretical concern that sustained IGF-1 elevation could promote proliferation of subclinical neoplasms — a concern shared with all GH-stimulating agents. Long-term safety data in healthy adults are not available.

Because these peptides are compounded rather than FDA-approved, product purity and potency are not standardized and vary by pharmacy. Contamination, incorrect dosing, and unlabeled additives are real risks with unregulated suppliers. Anyone considering these peptides should obtain them only through a licensed telehealth or clinical provider who sources from accredited compounding pharmacies, and should have baseline and follow-up IGF-1 testing. Individuals with active malignancy, diabetes, or a history of pituitary tumors should not use GH-stimulating peptides.